| Interactive pharmacometric applications using R and the shiny package J Wojciechowski, AM Hopkins, RN Upton CPT: pharmacometrics & systems pharmacology 4 (3), 146-159, 2015 | 99 | 2015 |
| Dashboard systems: implementing pharmacometrics from bench to bedside DR Mould, RN Upton, J Wojciechowski The AAPS journal 16, 925-937, 2014 | 54 | 2014 |
| Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies J Wojciechowski, RN Upton, DR Mould, MD Wiese, DJR Foster The AAPS Journal 19, 1136-1147, 2017 | 30 | 2017 |
| Dashboards for therapeutic monoclonal antibodies: learning and confirming DR Mould, RN Upton, J Wojciechowski, BL Phan, S Tse, MC Dubinsky The AAPS Journal 20, 1-12, 2018 | 19 | 2018 |
| Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy N Wabe, J Wojciechowski, MD Wechalekar, LG Cleland, L McWilliams, ... International Journal of Rheumatic Diseases 20 (10), 1447-1456, 2017 | 15 | 2017 |
| Population pharmacokinetics of abrocitinib in healthy individuals and patients with psoriasis or atopic dermatitis J Wojciechowski, BK Malhotra, X Wang, L Fostvedt, H Valdez, T Nicholas Clinical Pharmacokinetics 61 (5), 709-723, 2022 | 13 | 2022 |
| Population pharmacokinetic model of doxycycline plasma concentrations using pooled study data AM Hopkins, J Wojciechowski, AY Abuhelwa, S Mudge, RN Upton, ... Antimicrobial Agents and Chemotherapy 61 (3), 10.1128/aac. 02401-16, 2017 | 11 | 2017 |
| Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib J Wojciechowski, BK Malhotra, X Wang, L Fostvedt, H Valdez, T Nicholas British Journal of Clinical Pharmacology 88 (8), 3856-3871, 2022 | 8 | 2022 |
| Bayesian forecasting tool to predict the need for antidote in acute acetaminophen overdose J Desrochers, J Wojciechowski, W Klein‐Schwartz, JVS Gobburu, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (8 …, 2017 | 8 | 2017 |
| Model-optimized fluconazole dose selection for critically ill patients improves early pharmacodynamic target attainment without the need for therapeutic drug monitoring I Sandaradura, J Wojciechowski, DJE Marriott, RO Day, S Stocker, ... Antimicrobial Agents and Chemotherapy 65 (3), 10.1128/aac. 02019-20, 2021 | 7 | 2021 |
| A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine J Wojciechowski, MD Wiese, SM Proudman, DJR Foster, RN Upton British Journal of Clinical Pharmacology 79 (5), 777-788, 2015 | 5 | 2015 |
| Evolution of ritlecitinib population pharmacokinetic models during clinical drug development J Wojciechowski, V S Purohit, Y Huh, C Banfield, T Nicholas Clinical Pharmacokinetics 62 (12), 1765-1779, 2023 | 4 | 2023 |
| Opportunities and Challenges of Disease Progression Modeling in Drug Development–An IQ Perspective K Goteti, N Hanan, M Magee, J Wojciechowski, S Mensing, B Lalovic, ... Clinical Pharmacology & Therapeutics 114 (2), 266-274, 2023 | 3 | 2023 |
| Population PK and PD analysis of domagrozumab in pediatric patients with Duchenne muscular dystrophy J Wojciechowski, VS Purohit, LO Harnisch, P Dua, B Tan, T Nicholas Clinical Pharmacology & Therapeutics 112 (6), 1291-1302, 2022 | 3 | 2022 |
| Leveraging prior healthy participant pharmacokinetic data to evaluate the impact of renal and hepatic impairment on ritlecitinib pharmacokinetics V Purohit, Y Huh, J Wojciechowski, A Plotka, S Salts, J Antinew, ... The AAPS Journal 25 (3), 32, 2023 | 2 | 2023 |
| Pharmacokinetics‐based dosing strategies for therapeutic proteins in inflammatory bowel disease D Mould, R Upton, J Wojciechowski Quantitative Pharmacology and Individualized Therapy Strategies in …, 2019 | 1 | 2019 |
| Model‐Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate‐to‐Severe Ulcerative Colitis J Wojciechowski, A Mukherjee, C Banfield, T Nicholas Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
| Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm Y Huh, J Wojciechowski, VS Purohit Clinical Pharmacokinetics, 1-14, 2024 | | 2024 |
| Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers X Wang, P Gupta, BK Malhotra, SA Farooqui, VH Le, J Wojciechowski, ... Clinical Pharmacology in Drug Development 11 (9), 1036-1045, 2022 | | 2022 |
| USE OF A MODEL-INFORMED DRUG DEVELOPMENT (MIDD) APPROACH TO MITIGATE THE IMPACT OF DOSE INTERRUPTION DUE TO COVID-19 ON AN ONGOING P3 STUDY Y Huh, J Wojciechowski, V Purohit Clinical Pharmacology & Therapeutics, S79-S79, 2021 | | 2021 |
